Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Castleman's disease
ADR ID BADD_A09621
ADR Hierarchy
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.21      Haematopoietic neoplasms (excl leukaemias and lymphomas)
16.21.02      Lymphoproliferative disorders NEC (excl leukaemias and lymphomas)
16.21.02.005      Castleman's disease
01      Blood and lymphatic system disorders
01.13      Haematopoietic neoplasms (excl leukaemias and lymphomas)
01.13.02      Lymphoproliferative disorders NEC (excl leukaemias and lymphomas)
01.13.02.005      Castleman's disease
Description Large benign, hyperplastic lymph nodes. The more common hyaline vascular subtype is characterized by small hyaline vascular follicles and interfollicular capillary proliferations. Plasma cells are often present and represent another subtype with the plasma cells containing IgM and IMMUNOGLOBULIN A. [MeSH]
MedDRA Code 10050251
MeSH ID D005871
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Castleman's disease | Idiopathic plasmacytic lymphadenopathy | TAFRO syndrome | Castleman Disease | Angiofollicular Lymphoid Hyperplasia | Angiofollicular Lymphoid Hyperplasias | Hyperplasia, Angiofollicular Lymphoid | Lymphoid Hyperplasia, Angiofollicular | Castleman's Disease | Angiofollicular Lymph Node Hyperplasia | Hyperplasia, Giant Lymph Node | Lymph Node Hyperplasia, Giant | Angiofollicular Lymph Hyperplasia | Angiofollicular Lymph Hyperplasias | Hyperplasia, Angiofollicular Lymph | Lymph Hyperplasia, Angiofollicular | Castlemans Disease | Disease, Castlemans | Giant Lymph Node Hyperplasia | Castleman's Tumor | Castleman Tumor | Castlemans Tumor | Tumor, Castleman's
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D01831Prednisolone0.000035%
BADD_D02053Sofosbuvir0.000282%
BADD_D02105Tacrolimus0.000594%
The 1th Page    1    Total 1 Pages